Carregant...
A review of current and novel therapies for idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a progressively fibrotic interstitial lung disease that is associated with a median survival of 2-3 years from initial diagnosis. To date, there is no treatment approved for IPF in the United States, and only one pharmacological agent has been approved outside...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Pioneer Bioscience Publishing Company
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3548009/ https://ncbi.nlm.nih.gov/pubmed/23372951 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2072-1439.2012.12.07 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|